

OMEROS CORP  
Form 8-K  
March 13, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2012

## OMEROS CORPORATION

(Exact name of registrant as specified in its charter)

Washington  
(State or other jurisdiction of  
incorporation)

001-34475  
(Commission File Number)

91-1663741  
(IRS Employer  
Identification No.)

1420 Fifth Avenue, Suite 2600 Seattle, Washington 98101

(Address of principal executive offices, including zip code)

Edgar Filing: OMEROS CORP - Form 8-K

(206) 676-5000

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On March 13, 2012, we issued a press release announcing the results of our Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

| <b>Exhibit Number</b> |                                    | <b>Description</b> |
|-----------------------|------------------------------------|--------------------|
| 99.1                  | Press release dated March 13, 2012 |                    |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OMEROS CORPORATION**

By: /s/ Gregory A. Demopulos, M.D.  
Gregory A. Demopulos, M.D.  
President, Chief Executive Officer and  
Chairman of the Board of Directors

Date: March 13, 2012

**EXHIBIT INDEX**

| <b>Exhibit Number</b> | <b>Description</b>                 |
|-----------------------|------------------------------------|
| 99.1                  | Press release dated March 13, 2012 |